Loading clinical trials...
Loading clinical trials...
Effect of Haemoadsorption During Cardiopulmonary Bypass on Patients After Heart Transplantation
To investigate whether the use of haemoadsorption (HA) on cardiopulmonary bypass during heart transplantation (HTX) has an effect on circulating cytokine levels for the first 120 hours after HTX and induces a decreased inflammatory response, increased anti-inflammatory response or immunosuppressive response. Additionally, the influence of HA on primary graft dysfunction, postoperative cerebral dysfunction, postoperative fluid accumulation, renal dysfunction, duration of mechanical ventilation, length of ICU-stay and 30-day mortality should be investigated
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Divison of Cardiac Thoracic Vascular Anaesthesia and Intensive Care, Medical University of Vienna
Vienna, Vienna, Austria
Start Date
September 1, 2022
Primary Completion Date
December 31, 2025
Completion Date
June 30, 2026
Last Updated
May 9, 2025
40
ESTIMATED participants
CytoSorb Adsorber
DEVICE
Lead Sponsor
Medical University of Vienna
NCT07359690
NCT07291258
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions